Tandem Diabetes Care, Inc. (TNDM)
Automate Your Wheel Strategy on TNDM
With Tiblio's Option Bot, you can configure your own wheel strategy including TNDM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TNDM
- Rev/Share 16.5994
- Book/Share 2.3386
- PB 9.0995
- Debt/Equity 3.176
- CurrentRatio 2.3022
- ROIC -0.2786
- MktCap 1417401216.0
- FreeCF/Share -0.756
- PFCF -28.2351
- PE -7.6854
- Debt/Assets 0.5348
- DivYield 0
- ROE -0.8264
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TNDM | Mizuho | -- | Neutral | -- | $20 | April 10, 2025 |
| Downgrade | TNDM | Morgan Stanley | Overweight | Equal Weight | $45 | $22 | March 5, 2025 |
| Downgrade | TNDM | Citigroup | Buy | Neutral | $35 | $24 | March 4, 2025 |
| Downgrade | TNDM | Wells Fargo | Overweight | Equal Weight | $38 | $22 | March 3, 2025 |
| Downgrade | TNDM | Bernstein | Outperform | Market Perform | $35 | $25 | Feb. 28, 2025 |
| Initiation | TNDM | Goldman | -- | Neutral | -- | $46 | Oct. 4, 2024 |
| Initiation | TNDM | RBC Capital Mkts | -- | Outperform | -- | $65 | Oct. 2, 2024 |
| Initiation | TNDM | Morgan Stanley | -- | Equal Weight | -- | $45 | Aug. 22, 2024 |
News
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?
Read More
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
Read More
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
Read More
Reasons to Hold TNDM Stock in Your Portfolio for Now
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
Read More
Reasons to Hold TNDM Stock in Your Portfolio for Now
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.
Read More
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Negative
Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part.
Read More
Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer John Sheridan - President & Chief Executive Officer Mark Novara - Executive Vice President & Chief Commercial Officer Leigh Vosseller - Executive Vice President & Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matt Miksic - Barclays Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Shagun Singh - RBC Mike Kratky - Leerink Partners Danielle Antalffy - UBS Jayson Bedford - …
Read More
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago.
Read More
About Tandem Diabetes Care, Inc. (TNDM)
- IPO Date 2013-11-14
- Website https://www.tandemdiabetes.com
- Industry Medical - Devices
- CEO Mr. John F. Sheridan
- Employees 2650